MorphoSys AG (MOR) Stock News

USA - NASDAQ:MOR - US6177602025 - ADR

18.96 USD

+0.45 (+2.43%)

Last: 8/2/2024, 8:20:34 PM

18.96 USD

0 (0%)

After Hours: 8/2/2024, 8:20:34 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MOR Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Benzinga

Morpheus Launches $20 Million In Rewards For AI Compute Providers

a year ago - By: Halper Sadeh LLC - Mentions: SILK AFBI

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders

a year ago - By: InvestorPlace - Mentions: ACWI ACWX GCT NVS ...

3 Global Stocks to Buy to Escape the Volatility on Wall Street

2 years ago - By: Benzinga

MorphoSys: Q4 Earnings Insights

a year ago - By: MorphoSys AG

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

a year ago - By: Halper Sadeh LLC - Mentions: DM SHCR ALE

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders

a year ago - By: Halper Sadeh LLC - Mentions: ALLG BEST MGOL

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders

a year ago - By: Halper Sadeh LLC

MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders

a year ago - By: MorphoSys AG

MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders

2 years ago - By: InvestorPlace

MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024

2 years ago - By: MorphoSys AG

MorphoSys AG Reports First Quarter 2024 Financial Results

2 years ago - By: MorphoSys AG

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

2 years ago - By: MorphoSys AG

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

2 years ago - By: InvestorPlace - Mentions: MRNA MRK INCY ILMN ...

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise

2 years ago - By: InvestorPlace - Mentions: NVAS SAVA INCY NVS

Exit Now! 3 Biotech Stocks to Sell in February 2024

2 years ago - By: Seeking Alpha - Mentions: INCY

JMP cuts Incyte to market perform, cites need for acquisition (NASDAQ:INCY)

2 years ago - By: Seeking Alpha - Mentions: NVS

MorphoSys ADRs gain after definitive merger agreement with Novartis disclosed (NASDAQ:MOR)

2 years ago - By: Seeking Alpha - Mentions: NVS

Morphosys ADRs gain after definitive merger agreement with Novartis disclosed

2 years ago - By: Seeking Alpha - Mentions: NVS

MorphoSys drops amid speculation Novartis could walk from deal (NASDAQ:MOR)

2 years ago - By: Seeking Alpha - Mentions: NVS

MorphoSys ADRs drop amid speculation Novartis could walk from deal (NASDAQ:MOR)

2 years ago - By: Seeking Alpha - Mentions: NVS

MorphoSys ADRs drop amid speculation Novartis could walk from deal

2 years ago - By: Investor's Business Daily - Mentions: NVS INCY

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

2 years ago - By: Seeking Alpha - Mentions: INCY NVS

Incyte buys global rights for tafasitamab from MorphoSys (NASDAQ:INCY)